ARTICLE | Clinical News
PX-866: Interim Phase II data
May 28, 2012 7:00 AM UTC
Interim data from 15 evaluable patients with GBM at first recurrence in a 2-stage, single-arm, open-label, Canadian Phase II trial showed that 12 patients discontinued therapy after receiving a median...